Quest Diagnostics Incorporated (DGX) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 10YDoes not currently clear the 15%+, 20%+, or 30%+ revenue bars over 10Y.
- Score
- 18/100
- 10Y CAGR
- 3.9%
- Median YoY
- 1.6%
- YoY volatility
- σ 15.7pp· uneven
- Quarters ≥ 20%
- 4 of 40
- Negative quarters
- 16
- Valuation vs own 10Y history
- P/S 2.3x · 10Y median 1.8x · 100th percentile · as of Aug 19, 2026
How this score is computed
- Quarters at or above 20%: 4 of 40 → 4 of 40 pts
- Steadiness (typical swing 15.7pp) → 13.8 of 25 pts
- Pace (median 1.6% YoY) → 0 of 20 pts
- Latest quarter (10.2% YoY) → 0 of 15 pts
- Score: 18 of 100
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
Across metrics · 10Y
| Metric | 10Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 3.9% | 1.6% | 15.7pp | 4 of 40 | 16 |
| EPSEPS | 6% | 3.3% | 84.9pp | 10 of 40 | 17 |
| Op cash flowOperating cash flow | 8.8% | 8.1% | 54.8pp | 14 of 40 | 18 |
| EBITDAEBITDA | 2.5% | 0.7% | 45.1pp | 9 of 40 | 19 |
| FCFFree cash flow | 9.5% | 4.3% | 90.5pp | 16 of 39 | 19 |
Reported figures over 10Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: DGX on the compounders surface · All compounders, ranked